{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-004029","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2023-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.905806+00:00","generated_at":"2026-06-13T19:54:46.214397+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Arbutus doses first patient in Phase 2a triple combo arm adding nivolumab for chronic HBV","bullets":["First patient dosed in additional arm of AB-729 Phase 2a trial including nivolumab (Opdivo) with VTP-300.","Arm evaluates low-dose nivolumab plus VTP-300 boosters after AB-729 and NA therapy to reduce HBsAg in chronic HBV.","Preliminary data from this arm expected in 2024; original arm data expected H2 2023.","Enrollment complete in original arm; approximately 20 patients to be enrolled in new open-label arm."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-004029","json":"https://secwatch.observer/filing/0001171843-23-004029.json","markdown":"https://secwatch.observer/filing/0001171843-23-004029.md","text":"https://secwatch.observer/filing/0001171843-23-004029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323004029/0001171843-23-004029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323004029/f8k_062123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T19:54:46.214397+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}